Thrive Earlier Detection: Sam Asgarian, Frank Diehl, Dina Ciarimboli
Thrive Earlier Detection has appointed Sam Asgarian is its new chief medical officer, Frank Diehl as executive vice president of product solutions, and Dina Ciarimboli as chief legal officer.
Asgarian will lead the firm's medical strategy, including the integration of its CancerSEEK early detection test into routine medical care. He was most recently vice president of CVS Health's Transformation Health Product organization. Asgarian joined CVS as part of the Aetna acquisition, having served as the chief medical officer of Aetna's clinical services organization, overseeing medical management and clinical policy operations. He holds a BA in molecular and cell biology from the University of California at Berkeley, an MA in medical sciences from Loyola University Chicago, an MD from Tulane University, and an MBA from Cornell University.
Diehl is a globally recognized leader in cancer biology and detection who has pioneered the use of circulating tumor DNA to detect and track the progression of cancer. In 2008, he cofounded liquid biopsy firm Inostics, where he served as chief scientific officer through its acquisition by Sysmex, ultimately becoming CEO of Sysmex Inostics. Diehl completed his postdoc at the Ludwig Center for Cancer Genetics and Therapeutics at Johns Hopkins University and worked in the laboratory of Thrive cofounders Bert Vogelstein and Kenneth Kinzler. He holds a PhD in molecular pathology from Ruprecht-Karls University in Heidelberg, Germany.
Ciarimboli's appointment follows her interim role as general counsel. Prior to joining Thrive full time, she was general counsel at Third Rock Ventures. Before that, she served as general counsel to several venture capital firms focused on early-stage investing in various industries including biotech, diagnostics, medical devices, and healthcare services. Earlier, she served as an associate at Testa, Hurwitz & Thibeault, and as a senior associate at PricewaterhouseCoopers. Ciarimboli holds a BA in accounting and philosophy from Boston College and a JD from Boston College School of Law.
Micronoma: Magda Marquet
Micronoma, a startup using microbiome analysis for early cancer detection, has appointed Magda Marquet as chairman of the firm's board. She currently serves as the chairman of the board at Matrysis. Prior to Micronoma, she was the cofounder of Ajinomoto Althea and AltheaDx. Marquet also formerly served as chairman of the board of the University of California, San Diego Moores Cancer Center, where she now sits on the executive committee. Marquet has been an independent board member for Micronoma since 2019.
Theralink Technologies: Thomas Chilcott
Theralink Technologies has appointed Thomas Chilcott as the firm's CFO. Prior to Theralink, Chilcott served as CFO, secretary, and treasurer of Ampio Pharmaceuticals from 2017 to 2019. Before Ampio, Chilcott also served as president of Chilcott Consulting Group.
For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.